ImmunityBio, Inc.'s advances with Anktiva & rBCG show promise amid financial hurdles. Click here to find out why IBRX stock ...
Matt Galsky, MD, delved into the recent approval of a perioperative durvalumab regimen in muscle-invasive bladder cancer.
BeiGene has made the decision to end the clinical development program for ociperlimab (BGB-A1217) for the treatment of non-small cell lung cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback